Page Title
Pressemeldung

VPM contributes to the successful licensure of the novel malaria vaccine R21/Matrix-MTM for first use in Ghana

VPM contributes to the successful licensure of the novel malaria vaccine R21/Matrix-MTM for first use in Ghana.

Vakzine Projekt Management GmbH (VPM) is delighted to announce the successful licensing of the novel R21/Matrix-MTM Malaria Vaccine by the Ghana Food and Drugs Authority (FDA) for use in children as young as 5 months old up to 36 months old, in Ghana. This approval is an exciting milestone and was achieved by the joint global efforts of VPM, Serum Institute of India (SII), Oxford University, and DEK Vaccines Ltd (DEK). This synergistic collaboration facilitated the accelerated licensure process in Ghana and is a step forward on the path to ensuring vaccine equity in Africa.  READ MORE.